BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuo YC, Kohi MP, Naeger DM, Tong RT, Kolli KP, Taylor AG, Laberge JM, Kerlan RK, Fidelman N. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol. 2013;36:1336-1343. [PMID: 23864021 DOI: 10.1007/s00270-013-0698-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Qiu B, Zhao MF, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Dai S, Yao JN, Liu FQ. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension. World J Gastroenterol 2015; 21(43): 12439-12447 [PMID: 26604651 DOI: 10.3748/wjg.v21.i43.12439] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ruohoniemi DM, Taslakian B, Aaltonen EA, Hickey R, Patel A, Horn JC, Chiarello M, Mcdermott M. Comparative Analysis of Safety and Efficacy of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma in Patients with and without Pre-Existing Transjugular Intrahepatic Portosystemic Shunts. Journal of Vascular and Interventional Radiology 2020;31:409-15. [DOI: 10.1016/j.jvir.2019.11.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Park BV, Gaba RC, Lokken RP. Liver Infarction after Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma in the Setting of a Large Portosystemic Shunt. Semin Intervent Radiol. 2016;33:337-341. [PMID: 27904254 DOI: 10.1055/s-0036-1592319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Qiu B, Li K, Dong X, Liu FQ. Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Cardiovasc Intervent Radiol. 2017;40:1372-1382. [PMID: 28488102 DOI: 10.1007/s00270-017-1655-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
5 Wang Z, Zhang H, Zhao H, Wang X, Tsauo J, Luo X, Li X. Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Diagn Interv Radiol. 2014;20:487-491. [PMID: 25297389 DOI: 10.5152/dir.2014.13493] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
6 Yan J, Ying X, Malhotra A, Talenfeld A, Charalel R, Lee KS, Trost D, Kesselman A. Safety and Efficacy of Microwave Ablation for Hepatocellular Carcinoma in the Setting of Transjugular Intrahepatic Portosystemic Shunt. Cardiovasc Intervent Radiol 2021. [PMID: 34859308 DOI: 10.1007/s00270-021-03012-y] [Reference Citation Analysis]
7 Lokken RP, Kerlan RK , Jr, Chung YC, Chen YF, Mehta NJ, Yao FY, Fidelman N. Hepatic Toxicity After Selective Chemoembolization Is Associated With Decreased Survival Among Patients With Hepatocellular Carcinoma. AJR Am J Roentgenol 2021;216:1283-90. [PMID: 33703926 DOI: 10.2214/AJR.20.23478] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sellers CM, Nezami N, Schilsky ML, Kim HS. Transjugular intrahepatic portosystemic shunt as a bridge to liver transplant: Current state and future directions. Transplant Rev (Orlando) 2019;33:64-71. [PMID: 30477811 DOI: 10.1016/j.trre.2018.10.004] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Addissie BD, Roberts LR. Classification and staging of hepatocellular carcinoma: an aid to clinical decision-making. Clin Liver Dis. 2015;19:277-294. [PMID: 25921663 DOI: 10.1016/j.cld.2015.01.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
10 Gordon AC, Gupta AN, Gabr A, Thornburg BG, Kulik LM, Ganger DR, Maddur H, Flamm SL, Boike JR, Moore CM, Borja-Cacho D, Christopher DA, Katariya NN, Ladner DP, Caicedo-Ramirez JC, Riaz A, Salem R, Lewandowski RJ. Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation. J Vasc Interv Radiol 2021;32:211-9. [PMID: 33349507 DOI: 10.1016/j.jvir.2020.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Bermo M, Matesan MC, Itani M, Behnia F, Vesselle HJ. Hepatopulmonary shunting on Tc99m-MAA liver mapping: correlation with dynamic cross-sectional imaging and description of different shunting patterns. Abdom Radiol (NY) 2018;43:3001-8. [PMID: 29632990 DOI: 10.1007/s00261-018-1602-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Fan W, Guo J, Zhu B, Wang S, Yu L, Huang W, Fan H, Li F, Wu Y, Zhao Y, Wang Y, Xue M, Wang H, Li J. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. Eur Radiol 2021. [PMID: 33893536 DOI: 10.1007/s00330-021-07834-9] [Reference Citation Analysis]
13 Miura JT, Rilling WS, White SB, Hieb RA, Tutton SM, Patel PJ, Gamblin TC, Hohenwalter EJ. Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts. HPB (Oxford). 2015;17:707-712. [PMID: 26172137 DOI: 10.1111/hpb.12433] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
14 Allaire M, Rudler M, Thabut D. Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses…. Liver Int 2021;41:1734-43. [PMID: 34051060 DOI: 10.1111/liv.14977] [Reference Citation Analysis]
15 Luo J, Li M, Wu C, Zhu D, Wang H, Huang M, Jiang Z. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy for prevention of variceal rebleeding in patients with hepatocellular carcinoma meeting the Milan criteria. Eur J Gastroenterol Hepatol 2021;33:436-42. [PMID: 32398493 DOI: 10.1097/MEG.0000000000001750] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Padia SA, Chewning RH, Kogut MJ, Ingraham CR, Johnson GE, Bhattacharya R, Kwan SW, Monsky WL, Vaidya S, Hippe DS. Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts. Cardiovasc Intervent Radiol. 2015;38:913-921. [PMID: 25373795 DOI: 10.1007/s00270-014-1009-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
17 Shah KY, Gaba RC. Transjugular Intrahepatic Portosystemic Shunt Creation in Patients with Hepatocellular Carcinoma and Bleeding Gastric Varices: More Data, More Questions. J Vasc Interv Radiol 2021;32:971-3. [PMID: 34210483 DOI: 10.1016/j.jvir.2021.05.011] [Reference Citation Analysis]
18 Scaffaro LA, Kruel CD, Stella SF, Gravina GL, Machado Filho G, Borges de Almeida CP, Pinto LC, Alvares-da-Silva MR, Kruel CR. Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and Microspheres. Biomed Res Int 2015;2015:435120. [PMID: 26413523 DOI: 10.1155/2015/435120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
19 Bettinger D, Knüppel E, Euringer W, Spangenberg HC, Rössle M, Thimme R, Schultheiß M. Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2015;41:126-36. [PMID: 25329493 DOI: 10.1111/apt.12994] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
20 Chen X, Qiu ZK, Wang GB, Chen XL, Zhang FJ, Gao F. Effect of transjugular intrahepatic portosystemic shunt on transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. Diagn Interv Radiol 2021;27:671-6. [PMID: 34318755 DOI: 10.5152/dir.2021.20358] [Reference Citation Analysis]
21 Lu HL, Xuan FF, Luo YC, Qin X. Efficacy and safety of transjugular intrahepatic portosystemic shunt combined with transcatheter embolization/chemoembolization in hepatocellular carcinoma with portal hypertension and arterioportal shunt. Abdom Radiol (NY) 2021;46:5417-27. [PMID: 34302511 DOI: 10.1007/s00261-021-03214-5] [Reference Citation Analysis]